NANOBIOTIX (NANO) 35.24 EUR (-0.62%) | Healthcare Euronext / Paris

Nanobiotix is a French biopharmaceutical company specializing in nanotechnologies applied to oncology. It develops innovative treatments aimed at enhancing the efficacy of radiotherapy through nanoparticles that locally amplify the effects of radiation. Its lead candidate, NBTXR3, is in clinical development for several types of cancer. The company positions itself at the forefront of precision medicine and physical anti-cancer therapies.

Momentum is exceptionally strong and reflects a sharp rebound in market interest, with a very positive trend across multiple time horizons. This dynamic suggests a rerating in anticipation of clinical progress or improved sentiment on the story, but it also implies high sensitivity to regulatory, scientific, and financing announcements.

NANOBIOTIX

Trend Analysis of NANOBIOTIX

Want to see the full analysis?